Live Feeds
● LIVE Updated 1h ago · 13 sources tracked

Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots

Vaxcyte shares surged following positive late-stage trial results for its lead pneumococcal vaccine candidate, VAX-31. The vaccine met every primary goal in its adult Phase 3 trial named OPUS-1, demonstrating non-inferiority against established standard-of-care jabs from major pharmaceutical competitors. VAX-31 cleared a stringent bar against Pfizer's Prevnar 20 on all shared strains, while also performing strongly against Merck's Capvaxive. The successful trial data exceeded investor expectations, driving a sharp increase in the company stock value and positioning the biotech firm to challenge established players in a multibillion-dollar market.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (13)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Vaxcyte's VAX-31 pneumococcal vaccine met every primary goal in its pivotal adult Phase 3 trial named OPUS-1.
  • ✓ Vaxcyte shares jumped following the release of the Phase 3 trial results.
  • ✓ VAX-31 was tested against Pfizer's Prevnar 20 and Merck's Capvaxive.
🛡️ Source Corroboration: 13 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Vaxcyte released Phase 3 trial data showing its VAX-31 vaccine met all primary goals against shots from Pfizer and Merck.

Live updates

  1. Vaxcyte Stock Jumps As Pneumococcal Vaccine Matches Rivals

    Vaxcyte shares surged following positive late-stage trial results for its lead pneumococcal vaccine candidate, VAX-31. The vaccine met every primary goal in its adult Phase 3 trial named OPUS-1, demonstrating non-inferiority against established standard-of-care jabs from major pharmaceutical competitors. VAX-31 cleared a stringent bar against Pfizer's Prevnar 20 on all shared strains, while also performing strongly against Merck's Capvaxive. The successful trial data exceeded investor expectations, driving a sharp increase in the company stock value and positioning the biotech firm to challenge established players in a multibillion-dollar market.

    Why it matters

    The adult pneumococcal vaccine market represents a lucrative sector currently dominated by major pharmaceutical companies Pfizer and Merck. Vaxcyte entered this competitive space aiming to establish a new benchmark with its advanced candidate. The recent Phase 3 win provides the clinical backing necessary to challenge these established standard-of-care vaccines.

    What is confirmed

    • Vaxcyte's VAX-31 pneumococcal vaccine met every primary goal in its pivotal adult Phase 3 trial named OPUS-1.
    • Vaxcyte shares jumped following the release of the Phase 3 trial results.
    • VAX-31 was tested against Pfizer's Prevnar 20 and Merck's Capvaxive.

    Still unconfirmed

    • Vaxcyte's stock surged more than 57% in pre-market trading.
    • The adult pneumococcal vaccine market is valued at $7 billion or $8 billion.

    What to watch next

    • Further regulatory updates and filings for VAX-31
    • Additional clinical data or secondary endpoint readouts from the OPUS trial program
    Sources used for this update (14)
    1. Fierce Biotech — Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
    2. BioPharma Dive — Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
    3. Investor's Business Daily — Small Biotech Squares Up To Pfizer, Merck In $7 Billion Market
    4. Barron's — Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
    5. STAT — Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
    6. BioSpace — Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
    7. TIKR.com — Vaxcyte Soars 36% on Phase 3 Pneumococcal Vaccine Win That “Sets a New Benchmark”
    8. contents.premium.naver.com — 📬 미국 주식 데일리 종목 분석 (2026.10.06)
    9. Yahoo Finance — NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test
    10. www.biospace.com — Vaxcyte rises as pneumococcal shot establishes ‘new ...
    11. finance.yahoo.com — Vaxcyte’s stock up after pneumococcal vaccine proves non ...
    12. finance.yahoo.com — Vaxcyte Soars 36% on Phase 3 Pneumococcal Vaccine Win That ...
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community